Crestor Developer Sees Sales Doubling On Lower-Priced Drugs
- Shionogi made decision to stay away from expensive category
- CEO says in interview that ``partnerships are the way to go''
This article is for subscribers only.
Across the pharmaceutical industry, companies have rushed towards medicines with sky-high prices -- making bets in lucrative areas like complex cancer treatments and even gene therapy that could come with a $1 million price tag.
Japan’s Shionogi & Co., best known for its early development of the blockbuster cholesterol medicine Crestor, says it’s making a conscious decision to buck the trend -- and aims to double its revenue in the next five years through that strategy.